U.S. Gadolinium-based Contrast Media Market Size, Share & Trends Analysis Report By Type (Extracellular Agents, Blood Pool Agents, Hepatobiliary Agents), By Modality, By Indication, And Segment Forecasts, 2020 - 2027
This report can be delivered to the clients within 72 Business Hours
U.S. Gadolinium-based Contrast Media Market Growth & Trends
The U.S. gadolinium-based contrast media market size is expected to reach USD 766.4 million by 2027, expanding at a CAGR of 4.7%, according to a new report by Grand View Research, Inc. Increasing prevalence of long term diseases and complex comorbidities and advancement in technologies are expected to propel market growth over the forecast period. In addition, label expansions strategies such as mergers and acquisitions by key players to enhance their market position will further contribute to market growth.
Acquisitions by companies assist in increasing their presence with a wider geographical reach and stronger portfolios. In addition, technological advancements such as the introduction of digital solutions aiding the management of contrast agent injection are anticipated to drive the market. For instance, in November 2019, U.S. FDA approved a Macrocyclic MRI Contrast Agent named Clariscan developed by GE Healthcare, which is used to detect and visualize areas with disruption of the blood-brain barrier in adult and pediatric patient.
Gadolinium-based Contrast Agents (GBCAs) are used in about one in three MRI scans to improve the clarity of the images or pictures of the body’s internal structures. The GBCA’s helps in improving the visibility of inflammation, tumors, blood vessels, and, for some organs, blood supply. Furthermore, according to the National Health Council, in 2020, nearly 157.0 million people in the U.S. were affected by chronic diseases, out of which around 81.0 million had multiple conditions, which is indicative of a high incidence of chronic conditions. The increasing prevalence of chronic diseases and comorbidities is driving the market.
U.S. Gadolinium-based Contrast Media Market Report Highlights
U.S. Gadolinium-based Contrast Media Market Growth & Trends
The U.S. gadolinium-based contrast media market size is expected to reach USD 766.4 million by 2027, expanding at a CAGR of 4.7%, according to a new report by Grand View Research, Inc. Increasing prevalence of long term diseases and complex comorbidities and advancement in technologies are expected to propel market growth over the forecast period. In addition, label expansions strategies such as mergers and acquisitions by key players to enhance their market position will further contribute to market growth.
Acquisitions by companies assist in increasing their presence with a wider geographical reach and stronger portfolios. In addition, technological advancements such as the introduction of digital solutions aiding the management of contrast agent injection are anticipated to drive the market. For instance, in November 2019, U.S. FDA approved a Macrocyclic MRI Contrast Agent named Clariscan developed by GE Healthcare, which is used to detect and visualize areas with disruption of the blood-brain barrier in adult and pediatric patient.
Gadolinium-based Contrast Agents (GBCAs) are used in about one in three MRI scans to improve the clarity of the images or pictures of the body’s internal structures. The GBCA’s helps in improving the visibility of inflammation, tumors, blood vessels, and, for some organs, blood supply. Furthermore, according to the National Health Council, in 2020, nearly 157.0 million people in the U.S. were affected by chronic diseases, out of which around 81.0 million had multiple conditions, which is indicative of a high incidence of chronic conditions. The increasing prevalence of chronic diseases and comorbidities is driving the market.
U.S. Gadolinium-based Contrast Media Market Report Highlights
- The extracellular agents segment spearheaded the market in 2019 as they are most commonly used in the imaging of tumor and inflammation as well as in Magnetic Resonance Arthrography (MRA)
- The MRI segment was the largest in terms of revenue share in 2019 and the market’s best option for imaging of soft tissues, visualizing lesions for detection of neurological disorders, and liver diseases
- The neurology segment dominated the market in 2019. The cardiovascular segment is expected to witness the highest CAGR over the forecast period. This can be attributed to technological advancements in the field.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 Objectives
1.9.1 Objective - 1:
1.9.2 Objective - 2:
1.9.3 Objective - 3:
1.9.4 Objective - 4:
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 U.S. GADOLINIUM-BASED CONTRAST MEDIA MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Parent Market Outlook
3.2 Ancillary Market Outlook
3.3 Market Segmentation And Scope
3.4 Market Driver Analysis
3.4.1 Increase In The Prevalence Of Long-Term Diseases And Complex Comorbidities
3.4.2 Technological Advancements
3.4.3 Label Expansions
3.5 Market Restraint Analysis
3.5.1 Rising Concern About The Risk Of Gadolinium Retention In The Brain
3.6 Industry Challenges
3.7 Major Deals And Strategic Alliances Analysis
3.8 Market Entry Strategies
3.9 User Perspective Analysis
3.9.1 Consumer Behavior Analysis
3.9.2 Market Influencer Analysis
3.9.3 List Of Key End Users
3.10 Regulatory Framework
3.11 Reimbursement Framework
3.12 Standards & Compliances
3.13 Penetration & Growth Prospect Mapping
3.14 Porter’s Five Forces Analysis
3.15 PESTEL Analysis
CHAPTER 4 THE U.S. GADOLINIUM-BASED CONTRAST MEDIA MARKET: TYPE SEGMENT ANALYSIS
4.1 The U.S. Gadolinium -Based Contrast Media: Type Market Share Analysis, 2019 & 2027
4.2 Extracellular Agents
4.2.1 Extracellular Agents Market, 2016 - 2027 (USD Million)
4.3 Blood Pool Agents
4.3.1 Blood Pool Agentsmarket, 2016 - 2027 (USD Million)
4.4 Hepatobiliary Agents
4.4.1 Hepatobiliary Agents Market, 2016 - 2027 (USD Million)
CHAPTER 5 THE U.S. GADOLINIUM-BASED CONTRAST MEDIA MARKET: MODALITY SEGMENT ANALYSIS
5.1 The U.S. Gadolinium-Based Contrast Media: Market Share Analysis, 2019 & 2027
5.2 Magnetic Resonance Imaging (MRI)
5.2.1 MRI Market, 2016 - 2027 (USD Million)
5.3 Magnetic Resonance Angiography (MRA)
5.3.1 MRA Market, 2016 - 2027 (USD Million)
CHAPTER 6 U.S. GADOLINIUM-BASED CONTRAST MEDIA MARKET: INDICATION SEGMENT ANALYSIS
6.1 The U.S. Gadolinium-based Contrast Media: Market Share Analysis, 2018 & 2027
6.2 Cardiovascular
6.2.1 Cardiovascular Market, 2016 - 2027 (USD Million)
6.3 Cancer
6.3.1 Cancer Market, 2016 - 2027 (USD Million)
6.4 Neurology
6.4.1 Neurology Market, 2016 - 2027 (USD Million)
6.5 Others
6.5.1 Others Market, 2016 - 2027 (USD Million)
CHAPTER 7 COMPANY PROFILES
7.1 Company Profiles
7.1.1 Bayer AG
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product benchmarking
7.1.1.4 Strategic initiatives
7.1.2 GE HEALTHCARE
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic initiatives
7.1.3 Guerbet
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Product benchmarking
7.1.3.4 Strategic initiatives
7.1.4 Lantheus Medical Imaging, Inc
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic initiatives
7.1.5 Bracco Diagnostic Inc.
7.1.5.1 Company overview
7.1.5.2 Product benchmarking
7.1.5.3 Strategic initiatives
7.1.6 Trivitron Healthcare
7.1.6.1 Company overview
7.1.6.2 Product benchmarking
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 Objectives
1.9.1 Objective - 1:
1.9.2 Objective - 2:
1.9.3 Objective - 3:
1.9.4 Objective - 4:
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 U.S. GADOLINIUM-BASED CONTRAST MEDIA MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Parent Market Outlook
3.2 Ancillary Market Outlook
3.3 Market Segmentation And Scope
3.4 Market Driver Analysis
3.4.1 Increase In The Prevalence Of Long-Term Diseases And Complex Comorbidities
3.4.2 Technological Advancements
3.4.3 Label Expansions
3.5 Market Restraint Analysis
3.5.1 Rising Concern About The Risk Of Gadolinium Retention In The Brain
3.6 Industry Challenges
3.7 Major Deals And Strategic Alliances Analysis
3.8 Market Entry Strategies
3.9 User Perspective Analysis
3.9.1 Consumer Behavior Analysis
3.9.2 Market Influencer Analysis
3.9.3 List Of Key End Users
3.10 Regulatory Framework
3.11 Reimbursement Framework
3.12 Standards & Compliances
3.13 Penetration & Growth Prospect Mapping
3.14 Porter’s Five Forces Analysis
3.15 PESTEL Analysis
CHAPTER 4 THE U.S. GADOLINIUM-BASED CONTRAST MEDIA MARKET: TYPE SEGMENT ANALYSIS
4.1 The U.S. Gadolinium -Based Contrast Media: Type Market Share Analysis, 2019 & 2027
4.2 Extracellular Agents
4.2.1 Extracellular Agents Market, 2016 - 2027 (USD Million)
4.3 Blood Pool Agents
4.3.1 Blood Pool Agentsmarket, 2016 - 2027 (USD Million)
4.4 Hepatobiliary Agents
4.4.1 Hepatobiliary Agents Market, 2016 - 2027 (USD Million)
CHAPTER 5 THE U.S. GADOLINIUM-BASED CONTRAST MEDIA MARKET: MODALITY SEGMENT ANALYSIS
5.1 The U.S. Gadolinium-Based Contrast Media: Market Share Analysis, 2019 & 2027
5.2 Magnetic Resonance Imaging (MRI)
5.2.1 MRI Market, 2016 - 2027 (USD Million)
5.3 Magnetic Resonance Angiography (MRA)
5.3.1 MRA Market, 2016 - 2027 (USD Million)
CHAPTER 6 U.S. GADOLINIUM-BASED CONTRAST MEDIA MARKET: INDICATION SEGMENT ANALYSIS
6.1 The U.S. Gadolinium-based Contrast Media: Market Share Analysis, 2018 & 2027
6.2 Cardiovascular
6.2.1 Cardiovascular Market, 2016 - 2027 (USD Million)
6.3 Cancer
6.3.1 Cancer Market, 2016 - 2027 (USD Million)
6.4 Neurology
6.4.1 Neurology Market, 2016 - 2027 (USD Million)
6.5 Others
6.5.1 Others Market, 2016 - 2027 (USD Million)
CHAPTER 7 COMPANY PROFILES
7.1 Company Profiles
7.1.1 Bayer AG
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product benchmarking
7.1.1.4 Strategic initiatives
7.1.2 GE HEALTHCARE
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic initiatives
7.1.3 Guerbet
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Product benchmarking
7.1.3.4 Strategic initiatives
7.1.4 Lantheus Medical Imaging, Inc
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic initiatives
7.1.5 Bracco Diagnostic Inc.
7.1.5.1 Company overview
7.1.5.2 Product benchmarking
7.1.5.3 Strategic initiatives
7.1.6 Trivitron Healthcare
7.1.6.1 Company overview
7.1.6.2 Product benchmarking
LIST OF TABLES
Table 1 List of secondary sources
Table 1 List of secondary sources
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity Flow Analysis
Fig. 9 Volume Price Analysis
Fig. 10 The U.S. gadolinium-based contrast media market snapshot (2019)
Fig. 11 The U.S. gadolinium-based contrast media market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 The U.S. gadolinium-based contrast media market Type outlook: Segment dashboard
Fig. 18 The U.S. gadolinium-based contrast media market: Type movement analysis
Fig. 19 Extracellular agents market, 2016 - 2027 (USD Million)
Fig. 20 Blood pool agents market, 2016 - 2027 (USD Million)
Fig. 21 Hepatobiliary agents market, 2016 - 2027 (USD Million)
Fig. 22 The U.S. gadolinium-based contrast media market modality outlook: Segment dashboard
Fig. 23 The U.S. gadolinium-based contrast media market: modality movement analysis
Fig. 24 MRI market, 2016 - 2027 (USD Million)
Fig. 25 MRA market, 2016 - 2027 (USD Million)
Fig. 26 The U.S. gadolinium-based contrast media market indication outlook: Segment dashboard
Fig. 27 The U.S. gadolinium-based contrast media market: indication movement analysis
Fig. 28 Cardiovascular conditions market, 2016 - 2027 (USD Million)
Fig. 29 Cancer market, 2016 - 2027 (USD Million)
Fig. 30 Neurology market, 2016 - 2027 (USD Million)
Fig. 31 Others market, 2016 - 2027 (USD Million)
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity Flow Analysis
Fig. 9 Volume Price Analysis
Fig. 10 The U.S. gadolinium-based contrast media market snapshot (2019)
Fig. 11 The U.S. gadolinium-based contrast media market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 The U.S. gadolinium-based contrast media market Type outlook: Segment dashboard
Fig. 18 The U.S. gadolinium-based contrast media market: Type movement analysis
Fig. 19 Extracellular agents market, 2016 - 2027 (USD Million)
Fig. 20 Blood pool agents market, 2016 - 2027 (USD Million)
Fig. 21 Hepatobiliary agents market, 2016 - 2027 (USD Million)
Fig. 22 The U.S. gadolinium-based contrast media market modality outlook: Segment dashboard
Fig. 23 The U.S. gadolinium-based contrast media market: modality movement analysis
Fig. 24 MRI market, 2016 - 2027 (USD Million)
Fig. 25 MRA market, 2016 - 2027 (USD Million)
Fig. 26 The U.S. gadolinium-based contrast media market indication outlook: Segment dashboard
Fig. 27 The U.S. gadolinium-based contrast media market: indication movement analysis
Fig. 28 Cardiovascular conditions market, 2016 - 2027 (USD Million)
Fig. 29 Cancer market, 2016 - 2027 (USD Million)
Fig. 30 Neurology market, 2016 - 2027 (USD Million)
Fig. 31 Others market, 2016 - 2027 (USD Million)
